The MPN AA is delighted to advise that, as of today, 1 September 2025, ruxolitinib is available on the pharmaceutical benefits schedule (PBS) for the treatment of adult patients with […]
A European study has just been released suggesting a new way to monitor polycythemia vera patients’ disease activity. Titled ‘Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in […]
‘What does optimal management of MPNs look like in 2025?’ MPN AA, in partnership with the University of Western Australia School of Biomedical Sciences and Royal Perth Hospital, is proudly […]
A recently published research article may be of interest to MPN patients with the Jak2 mutation. It is titled ‘Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With […]
Haematologist Dr Cecily Forsyth and MPN AA advocate Nathalie Cook OAM have prepared an explanatory video for patients about the current Australian Pegasys supply. The video addresses the current and […]
The MPN AA has been advised of some very encouraging news about the Pegasys supply in Australia into the future. For details, please see the attached letter from the Australian […]
The MPNAA has just become aware of this extensive article about interferon, written by US haematologists and published in 2024 in Therapeutic Advances in Hematology. As so many more MPN […]
We are thrilled to advise that the Pharmaceutical Benefits Committee (PBAC) at its March meeting has recommended that ruxolitinib (jakavi) be listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]
The MPN AA is delighted to advise that the Australian government has now approved the inclusion of momelotinib, now known as OMJJARA, onto the Pharmaceutical Benefits Scheme (PBS). Momelotinib was […]
